MétaCan
Menu
← Retour à la cohorte
Enregistrement W4405039389 · doi:10.1182/blood-2024-208314

Metabolic and Cell Cycle Proteins As Novel Targets of Selinexor Activity in Diffuse Large B Cell Lymphoma

2024· article· en· W4405039389 sur OpenAlexaff
Kyla L. Trkulja, Will Tong, Daisy Tran, Meng Li, Evelyn Teh, Susanne Penny, Devanand M. Pinto, Armand Keating, John Kuruvilla, Rob C. Laister

Notice bibliographique

RevueBlood · 2024
Typearticle
Langueen
DomaineBiochemistry, Genetics and Molecular Biology
ThématiqueCancer, Hypoxia, and Metabolism
Établissements canadiensPrincess Margaret Cancer CentreUniversity of Toronto
Organismes subventionnairesnon disponible
Mots-clésDiffuse large B-cell lymphomaLymphomaCell cycleComputational biologyCellBiologyCell biologyCancer researchMedicineBiochemistryImmunology

Résumé

récupéré en direct d'OpenAlex

Background Diffuse large B cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma (NHL) and has poor outcomes in the relapsed/refractory (R/R) setting. Recent years have identified Exportin-1 (XPO1), a nuclear export protein, as a negative prognostic factor in several cancer types including DLBCL. Selinexor, an orally-available inhibitor of XPO1 has modest activity in R/R DLBCL, but knowledge gaps in understanding how XPO1 drives DLBCL are preventing effective use of selinexor in the clinic. Specifically, large-scale proteomics studies investigating which proteins are exported to the cytoplasm by XPO1 are lacking, and mechanisms of activity of selinexor-mediated XPO1 inhibition in DLBCL have not been well described. Therefore, we analyzed selinexor's effects on DLBCL metabolism and conducted a mass spectrometry analysis of proteins to determine which pathways are modulated by selinexor-mediated XPO1 inhibition. Methods DLBCL cell lines (HBL-1, OCI-Ly2, OCI-Ly8) were treated with selinexor for 24 hours and changes in mitochondrial and glycolytic ATP production was measured using an XFe 96 Agilent Seahorse bioanalyzer. Cells were treated with 0.5µM selinexor for 24 hours and replicates were subject to proteomic analysis via mass spectrometry. Proteins identified as having significant changes in abundance upon selinexor treatment were interrogated with Reactome to determine which pathways are modulated by the compound in DLBCL (Milacic et al., 2024). The sequences of proteins from the top pathways, as well as those of metabolic proteins of interest, were analyzed using the LocNES nuclear export sequence identifier to determine which of these proteins may be canonical XPO1 cargo molecules (Xu et al., 2014). Results Selinexor significantly reduced both mitochondrial and glycolytic ATP production (p<0.001) in all cell lines, as measured by oxygen consumption rate (OCR) and extracellular acidification rate (ECAR). Cell viability at this time point between cells treated and untreated with selinexor were not statistically significant, indicating that these metabolic changes were due to XPO1 inhibition and not cell death. Mass spectrometry analysis identified 6313 proteins, of which 126 showed a statistically significant change (p<0.05) in abundance with selinexor treatment (87 downregulated and 39 upregulated). The top pathways modified by selinexor included mitotic cell cycle control, mRNA splicing, rRNA modification, and RNA binding proteins, all of which were downregulated by the treatment. Canonical nuclear export sequences were identified in several selinexor-modulated proteins in these pathways, including cyclin B2, ORC1, LMNB1, HNRPC, and GAR1. Several metabolic proteins were affected by selinexor treatment, most notably ACADS, which catalyzes lipid metabolism via fatty acid oxidation. ACADS showed a decreased abundance in response to selinexor treatment, suggesting a mechanism by which the drug exerts its metabolic effects via inhibition of fatty acid oxidation and subsequent ATP production. Upon further analysis, the peptide sequence of the protein was also found to harbour a nuclear export sequence, indicating it is a potentially relevant XPO1 cargo molecule to the anti-lymphoma effects of selinexor. Conclusion Selinexor inhibits glycolytic and mitochondrial metabolism in DLBCL, which appears to be driven by blocking the nuclear export of enzymes involved in metabolism such as ACADS, which catalyzes ATP production via fatty acid oxidation. Selinexor is also able to decrease the abundance of proteins involved in cell cycle progression and RNA metabolism. We have identified several novel proteins that can be modulated by selinexor in DLBCL that may contribute to its mechanisms of anti-cancer activity in lymphoma. We aim to validate XPO1 targets of interest in our dataset. Future work will verify which of these proteins are XPO1 cargo molecules via proximity-ligation assays to reveal how the treatment exerts its cytotoxic effects in DLBCL.

Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.

Comment cette classification a été obtenuedéplier

Prédiction machine sur la base complète

Imitation des enseignants

Ni prévalence calibrée, ni vérité terrain. Validation humaine à venir. Le volet Gemma est une étiquette directe du modèle pour chaque travail de la base, lue sur la notice réduite au titre. Le volet Codex est un classifieur appris des 10 348 étiquettes directes de Codex et calibré sur les taux pondérés de l'échantillon; les champs sans appui suffisant ne portent aucun appel Codex. Le mode candidate est l'union des deux volets; le consensus est leur intersection. Ces sorties portent le statut machine_predicted_unvalidated et ne sont pas des étiquettes humaines.

score de la tête « metaresearch » (Codex)0,000
score de la tête « metaresearch » (Gemma)0,000
Version: metacan-v3-hybrid-931329e0061cStatut de validation: machine_predicted_unvalidated
Catégories candidatesaucune
Catégories consensuellesaucune
DomaineSignal candidat: aucune · Signal consensuel: aucune
Devis d'étudeSignal candidat: Expérimental (laboratoire) · Signal consensuel: Expérimental (laboratoire)
GenreSignal candidat: Empirique · Signal consensuel: Empirique
Score de désaccord entre enseignants0,001
Score d'incertitude au seuil0,003

Scores du classifieur distillé par catégorie (deux têtes)

CatégorieCodexGemma
Métarecherche0,0000,000
Méta-épidémiologie (sens strict)0,0000,000
Méta-épidémiologie (sens large)0,0000,000
Bibliométrie0,0000,000
Études des sciences et des technologies0,0000,000
Communication savante0,0000,000
Science ouverte0,0000,000
Intégrité de la recherche0,0000,000
Charge utile insuffisante (le modèle a refusé de juger)0,0010,000

Scores machine (provisoires)

Les deux têtes enseignantes du modèle étudiant, lues sur ce travail. Un score ordonne la base pour la relecture; il n'affirme jamais une catégorie, et le statut de validation accompagne chaque rangée tel quel.

Scores de référence d'un modèle non mature (critères de maturité non atteints, 7 itérations). Un score ordonne; il n'affirme jamais une catégorie.

Tête enseignante Opus0,005
Tête enseignante GPT0,222
Écart entre enseignants0,217 · la distance entre les deux têtes enseignantes sur ce seul travail
Statut de validationscore_only:v0-immature-baseline · tel quel depuis la passe de notation : score_only signifie que le nombre peut ordonner les travaux, et qu'aucune étiquette de catégorie n'en découle

Classification

machine, non validée

Prédiction automatique; un appel candidat d’une seule source (Gemma direct ou Codex distillé), pas un consensus.

Les modèles n’ont appliqué aucune catégorie : rien dans la taxonomie ne correspondait à ce travail.
Devis d'étudeExpérimental (laboratoire)
Domainenon disponible
GenreEmpirique

Le détail, modèle par modèle et score par score, se trouve en fin de page sous « Comment cette classification a été obtenue ».

En bref

Citations0
Publié2024
Routes d'admission1
Résumé présentoui

Explorer davantage

Même revueBlood→Même sujetCancer, Hypoxia, and Metabolism→Travaux en français237 207→